Imugene Ltd

IMU

Company Profile

  • Business description

    Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

  • Contact

    4-6 Bligh Street
    Suite 12.01, Level 12
    SydneyNSW2000
    AUS

    T: +61 294230881

    https://www.imugene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    5

Stocks News & Analysis

stocks

Strong finish to the year for overvalued ASX share

A great fiscal 2025 but investors are ahead of themselves.
stocks

Our three most overvalued ASX shares

These three companies are trading at a significant premium to our fair value.
stocks

What does big US court decision mean for Google’s parent company Alphabet?

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,080.7039.80-0.44%
CAC 407,749.3914.550.19%
DAX 4023,718.4588.68-0.37%
Dow JONES (US)45,693.85178.900.39%
FTSE 1009,242.5321.090.23%
HKSE25,938.13304.221.19%
NASDAQ21,856.4557.750.26%
Nikkei 22543,459.29184.52-0.42%
NZX 50 Index13,253.7327.41-0.21%
S&P 5006,508.8913.740.21%
S&P/ASX 2008,803.5037.40-0.42%
SSE Composite Index3,807.2919.55-0.51%

Market Movers